Prelude Therapeutics (PRLD) Consolidated Net Income (2019 - 2026)
Prelude Therapeutics (PRLD) posted Consolidated Net Income of -$34.4 million for Q1 2026, down 90.49% sequentially from -$18.1 million in Q4 2025, and up 40.15% YoY from -$24.6 million in Q1 2025.
Prelude Therapeutics (PRLD) Consolidated Net Income (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Consolidated Net Income for 8 years, with the latest figure at -$34.4 million in Q1 2026.
- Quarterly Consolidated Net Income rose 40.15% year-over-year to -$34.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$149.0 million (up 39.97% YoY) and the FY2025 annual result came in at -$316.5 million, up 1.83% from the prior year.
- Consolidated Net Income retreated to -$34.4 million in Q1 2026 per PRLD's latest filing, from -$18.1 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$18.1 million in Q4 2025 and troughed at -$144.4 million in Q4 2022.
- A 5-year average of -$52.4 million and a median of -$41.6 million in 2022 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2022 and 2024: Consolidated Net Income jumped 83.64% in 2022, then plunged 112.54% in 2024.
- Over 5 years, Consolidated Net Income stood at -$144.4 million in 2022, then jumped by 73.79% to -$37.9 million in 2023, then gained by 9.24% to -$34.4 million in 2024, then surged by 47.38% to -$18.1 million in 2025, then tumbled by 90.49% to -$34.4 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$34.4 million, -$18.1 million, and -$42.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | -52.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.71 Mn |
| Mar 31, 2026 | -34.44 Mn |
| Dec 31, 2025 | -18.08 Mn |
| Sep 30, 2025 | -42.02 Mn |
| Jun 30, 2025 | -54.47 Mn |
| Mar 31, 2025 | -57.55 Mn |
| Dec 31, 2024 | -34.36 Mn |
| Sep 30, 2024 | -76.48 Mn |
| Jun 30, 2024 | -79.85 Mn |
| Mar 31, 2024 | -77.64 Mn |
| Dec 31, 2023 | -37.86 Mn |
| Sep 30, 2023 | -35.99 Mn |
| Jun 30, 2023 | -37.80 Mn |
| Mar 31, 2023 | -38.22 Mn |
| Dec 31, 2022 | -144.44 Mn |
| Sep 30, 2022 | -42.51 Mn |
| Jun 30, 2022 | -37.16 Mn |
| Mar 31, 2022 | -41.59 Mn |
| Dec 31, 2021 | -108.38 Mn |
| Sep 30, 2021 | -170.14 Mn |